• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines N-alkylpyrrolidines
• Solvents and Organic Chemicals Organic Compounds Acids/Esters
• Solvents and Organic Chemicals Organic Compounds Hydrocarbons

Introduction to Compound with CAS No. 1356111-39-1 and Product Name: 1-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl]pyrrolidine

The compound with the CAS number 1356111-39-1 and the product name 1-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl]pyrrolidine represents a significant advancement in the field of pharmaceutical chemistry. This compound has garnered considerable attention due to its unique structural features and potential applications in drug development. The presence of a tetramethyl-1,3,2-dioxaborolan-2-yl moiety and a cyclohex-3-en backbone suggests a high degree of molecular complexity, which can be leveraged for designing novel therapeutic agents.

In recent years, the pharmaceutical industry has seen a surge in the development of boron-containing compounds, particularly those incorporating boronic acid or borate esters. These functionalities are widely recognized for their role in enhancing the bioactivity and pharmacokinetic properties of drug candidates. The tetramethyl-1,3,2-dioxaborolan-2-yl group in this compound is particularly noteworthy, as it provides a stable and versatile handle for further chemical modifications. This stability is crucial for applications in cross-coupling reactions, which are fundamental to modern synthetic organic chemistry.

The cyclohex-3-en moiety contributes to the compound's overall steric and electronic properties, influencing its interactions with biological targets. This structural feature is often employed in medicinal chemistry to optimize binding affinity and metabolic stability. The combination of these elements makes 1-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl]pyrrolidine a promising candidate for further exploration in the design of small-molecule drugs.

Recent studies have highlighted the importance of boron-containing compounds in the treatment of various diseases. For instance, boron neutron capture therapy (BNCT) has shown promise in cancer treatment due to the selective uptake of boron compounds by tumor cells. While this compound is not directly intended for BNCT, its boronate ester functionality could be exploited for similar therapeutic applications. The tetramethyl-1,3,2-dioxaborolan-2-yl group provides a stable platform for further derivatization, allowing researchers to fine-tune the compound's properties for specific biological targets.

The pyrrolidine ring is another key structural feature that contributes to the compound's potential bioactivity. Pyrrolidine derivatives are known to exhibit a wide range of pharmacological effects, including antiviral, anti-inflammatory, and anticancer activities. By incorporating this motif into the molecular framework, researchers can harness its known biological properties while also exploring new therapeutic avenues. The flexibility of the pyrrolidine ring allows for diverse conformational states, which can be advantageous in optimizing binding interactions with biological targets.

Advances in computational chemistry have significantly enhanced our ability to predict and design molecules with desired properties. Molecular modeling studies have shown that 1-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl]pyrrolidine exhibits favorable interactions with various protein targets. These simulations have guided the optimization of key pharmacophoric elements within the molecule, paving the way for more effective drug candidates. The integration of experimental data with computational predictions has become an indispensable tool in modern drug discovery.

The synthesis of this compound represents a testament to the progress made in synthetic methodologies over recent decades. The use of transition-metal-catalyzed cross-coupling reactions has revolutionized organic synthesis, enabling the construction of complex molecules with remarkable precision. The tetramethyl-1,3,2-dioxaborolan-2-yl group serves as an excellent substrate for such reactions, facilitating the introduction of diverse functional groups at strategic positions within the molecule. This synthetic versatility is crucial for generating libraries of compounds for high-throughput screening.

In conclusion, 1-[4-(tetramethyl-1,3,2-dioxaborolan - 2 - yl)cyclohex - 3 - en - 1 - yl]pyrrolidine stands as a promising candidate for further pharmaceutical development. Its unique structural features and potential bioactivity make it an attractive target for medicinal chemists seeking to design novel therapeutic agents. As research continues to uncover new applications for boron-containing compounds, this molecule may play a significant role in addressing unmet medical needs.

• 287944-06-3(2-(4-(tert-butyl)cyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane)
• 1046793-60-5(4-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)-1,4-oxazepane)
• 859219-41-3(4,4,5,5-tetramethyl-2-{spiro[4.5]dec-7-en-8-yl}-1,3,2-dioxaborolane)
• 1046793-62-7(1-methyl-4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl]piperazine)
• 1642583-50-3((1-Isopropyl-1,2,3,6-tetrahydropyridin-4-YL)boronic acid pinacol ester)
• 859217-85-9(4,4,5,5-Tetramethyl-2-(3,3,5,5-tetramethylcyclohex-1-en-1-yl)-1,3,2-dioxaborolane)
• 1046793-56-9(4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl]morpholine)
• 1257651-11-8(2,2,6,6-tetramethyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine)
• 859217-67-7(2-(4,4-dimethylcyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane)
• 859219-46-8(4,4,5,5-tetramethyl-2-{spiro[2.5]oct-5-en-6-yl}-1,3,2-dioxaborolane)